Search

Your search keyword '"Biological products industry -- Product development"' showing total 532 results

Search Constraints

Start Over You searched for: Descriptor "Biological products industry -- Product development" Remove constraint Descriptor: "Biological products industry -- Product development" Publisher right vision media Remove constraint Publisher: right vision media
532 results on '"Biological products industry -- Product development"'

Search Results

1. Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024

2. Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

3. Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXelleratetm

4. Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836

5. PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government's Project NextGen

6. Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF|GLIS AML

7. LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

8. Karolinska Development's portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine

9. The Positive Topline Results From Phase III Study of UCB|Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight

10. Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

11. Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting

12. Spine BioPharma, Inc. Unveils Completion Of Enrollment For Phase 3 Clinical Trial Of SB-01 To Address Chronic Low Back Pain

13. UCB and Biogen Announced Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

14. CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001

15. Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation

16. Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

17. Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada(r) In Second Pivotal Phase 3 Trial

18. GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1|2 Clinical Trial from the U.S. FDA

19. Vaxcyte Reports Positive Topline Data from Phase 1|2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine

20. FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

21. AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema

22. Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy

23. Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

24. WestGene advances clinical trials following dual IND approval for world's first EB virus-targeted mRNA therapeutic cancer vaccine

25. Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024

26. Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies

27. Ultimovacs ASA: Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024

28. OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

29. Dynavax Initiates Phase 1|2 Study of Novel Shingles Vaccine Program

30. Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults

31. Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

32. Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

33. Ultimovacs ASA: Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab

35. Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

36. BioInvent Presents Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA(r) (pembrolizumab) in Patients with Solid Tumors at ASCO 2024

37. Kiromic BioPharma Adds UPMC As Fourth Deltacel-01 Clinical Trial Site

38. Be Biopharma Unveils New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia

39. IMUNON Reports Site Activation for IMNN-101 Phase 1 Vaccine Study

40. HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

41. Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide

42. Lytix Biopharma AS: Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity

43. Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

44. Kiromic BioPharma reports favorable safety in Deltacel-01 clinical trial

45. Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort

46. Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

47. Kiromic BioPharma provides update on Deltacel-01 clinical trial results

48. BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA(r) (pembrolizumab)

49. Osivax Announced Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

50. Blue Lake Biotechnology reports interim clinical data in children for its RSV vaccine candidate

Catalog

Books, media, physical & digital resources